Structures by: Bis J. A.
Total: 30
C19H15N3O
C19H15N3O
Molecular Pharmaceutics (2007) 4, 3 401
a=18.715(8)Å b=7.228(3)Å c=23.208(9)Å
α=90.00° β=90.478(12)° γ=90.00°
C18H14N2O
C18H14N2O
Molecular Pharmaceutics (2007) 4, 3 401
a=9.906(12)Å b=21.65(3)Å c=7.590(9)Å
α=90.00° β=112.14(2)° γ=90.00°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=12.7871(17)Å b=7.2838(9)Å c=44.445(6)Å
α=90.00° β=90.895(3)° γ=90.00°
C19H15N3O
C19H15N3O
Molecular Pharmaceutics (2007) 4, 3 401
a=18.503(3)Å b=7.5019(10)Å c=21.971(3)Å
α=90.00° β=92.181(4)° γ=90.00°
C19H15N3O
C19H15N3O
Molecular Pharmaceutics (2007) 4, 3 401
a=7.616(2)Å b=10.003(3)Å c=22.497(6)Å
α=87.342(5)° β=81.024(6)° γ=69.737(6)°
C26H22N4O2
C26H22N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=13.223(3)Å b=6.1971(12)Å c=14.630(3)Å
α=90.00° β=113.661(3)° γ=90.00°
C26H20N4O2
C26H20N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=16.5421(17)Å b=7.5056(8)Å c=18.709(2)Å
α=90.00° β=106.763(2)° γ=90.00°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=20.866(6)Å b=7.437(2)Å c=6.7662(18)Å
α=90.00° β=98.142(5)° γ=90.00°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=3.8483(17)Å b=8.755(4)Å c=14.364(6)Å
α=96.647(7)° β=94.498(8)° γ=95.474(7)°
C26H22N4O2
C26H22N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=11.195(3)Å b=7.335(2)Å c=13.530(4)Å
α=90.00° β=99.465(7)° γ=90.00°
C26H20N4O2
C26H20N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=14.660(3)Å b=4.1100(8)Å c=18.290(4)Å
α=90.00° β=90.74(3)° γ=90.00°
C24H18N6O3
C24H18N6O3
Molecular Pharmaceutics (2007) 4, 3 401
a=7.889(3)Å b=8.156(3)Å c=19.673(7)Å
α=83.866(7)° β=85.627(6)° γ=63.512(5)°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=39.87(2)Å b=7.586(5)Å c=6.915(4)Å
α=90.00° β=91.972(19)° γ=90.00°
C18H14N4O2
C18H14N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=9.171(4)Å b=9.941(5)Å c=10.265(5)Å
α=95.674(8)° β=94.987(8)° γ=114.784(8)°
C30H24F4N4O4S
C30H24F4N4O4S
Molecular Pharmaceutics (2007) 4, 3 401
a=8.274(3)Å b=10.172(3)Å c=18.601(7)Å
α=87.521(7)° β=78.256(6)° γ=71.067(7)°
C18H14N2O
C18H14N2O
Molecular Pharmaceutics (2007) 4, 3 401
a=26.217(13)Å b=7.481(5)Å c=19.410(10)Å
α=90.00° β=128.310(14)° γ=90.00°
2-aminopyridinium isophthalate 1:1
(C5H7N2)(C8H5O4)
Crystal Growth & Design (2005) 5, 3 1169
a=12.5619(13)Å b=8.0768(9)Å c=12.2356(13)Å
α=90.00° β=109.831(2)° γ=90.00°
2-aminopyridinium terephthalate 2:1
(C5H7N2)2(C8H4O4)
Crystal Growth & Design (2005) 5, 3 1169
a=5.1991(8)Å b=14.606(2)Å c=11.1897(17)Å
α=90.00° β=95.094(3)° γ=90.00°
2-amino-5-picolinium benzoate 1:1
(C6H9N2)(C7H5O2)
Crystal Growth & Design (2005) 5, 3 1169
a=9.678(3)Å b=10.838(4)Å c=11.836(4)Å
α=90.00° β=111.210(6)° γ=90.00°
2-amino-5-picolinium 5-t-butylisophthalate
(C6H9N2)2(C12H12O4)
Crystal Growth & Design (2005) 5, 3 1169
a=8.5420(12)Å b=11.0504(16)Å c=13.0956(19)Å
α=101.086(2)° β=103.007(2)° γ=98.983(2)°
2-amino-5-picolinium terephthalate 2:1
(C6H9N2)(C8H4O4)0.5
Crystal Growth & Design (2005) 5, 3 1169
a=5.627(2)Å b=14.480(6)Å c=11.351(4)Å
α=90.00° β=99.622(7)° γ=90.00°
2-amino-5-picolinium adipate adipic acid 2:1:1
(C6H9N2)2(C6H8O4)(C6H10O4)
Crystal Growth & Design (2005) 5, 3 1169
a=5.0700(7)Å b=7.2081(10)Å c=18.388(3)Å
α=88.468(2)° β=85.015(2)° γ=72.373(2)°
2-amino-5-picolinium 2,5-thiophenedicarboxylate 2,5-thiophenedicarboxylic acid
2(C6H9N2),C6H4O4S,C6H2O4S
Crystal Growth & Design (2005) 5, 3 1169
a=14.7349(10)Å b=18.7523(12)Å c=9.0740(6)Å
α=90.00° β=90.00° γ=90.00°
2-amino-5-picolinium Indomethacine 1:1
(C6H9N2)(C19H15NO4Cl)
Crystal Growth & Design (2005) 5, 3 1169
a=12.5640(16)Å b=11.3377(14)Å c=30.501(4)Å
α=90.00° β=90.00° γ=90.00°
2-aminopyridinium 4-aminobenzoate 1:1
(C5H7N2)(C7H6NO2)
Crystal Growth & Design (2005) 5, 3 1169
a=18.932(2)Å b=5.6894(7)Å c=10.4151(13)Å
α=90.00° β=90.00° γ=90.00°
2-amino-5-methylpyridinium 2,6-naphthalenedicarboxylate 2:1
(C6H9N2)2(C12H6O2)
Crystal Growth & Design (2005) 5, 3 1169
a=5.834(2)Å b=16.260(7)Å c=10.985(4)Å
α=90.00° β=92.141(7)° γ=90.00°
C26H46N2O11S
C26H46N2O11S
Crystal Growth & Design (2014) 14, 2 775
a=14.497(5)Å b=17.021(6)Å c=12.332(4)Å
α=90° β=103.739(16)° γ=90°
3:2 co-crystal of 4,4'-biphenol and 2-aminopyridine
C23H21N2O3
Crystal Growth & Design (2006) 6, 12 2648
a=11.3359(16)Å b=20.632(3)Å c=8.0994(12)Å
α=90.00° β=94.359(3)° γ=90.00°
1:2 Co-crystal of 4,4'-biphenol and caprolactam
C12H10O2,2(C6H11NO)
Crystal Growth & Design (2006) 6, 12 2648
a=6.6784(9)Å b=15.130(2)Å c=22.084(3)Å
α=90.00° β=92.200(2)° γ=90.00°
1:2 co-crystal of resorcinol and caprolactam
C18H18N2O3
Crystal Growth & Design (2006) 6, 12 2648
a=6.5876(13)Å b=9.3924(19)Å c=16.172(3)Å
α=76.124(4)° β=79.358(4)° γ=78.071(4)°